EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation

Megan M McNiff, Sheila Hawkins, Bine Haase, Joanne Bullivant, Tammy McIver, Olga Mitelman, Nicholas Emery, Giorgio Tasca, Nicol Voermans, Jordi Diaz-Manera

Journal of Neuromuscular Diseases · 05.03.2024 · 11 (2) · 459-472

DOI: 10.3233/jnd-230171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 24.01.2024. Verfasst von Megan M McNiff und 9 weiteren Autor:innen. Beteiligte Einrichtung: John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by progressive muscle weakness leading to permanent disability. There are no curative treatments, however, there are several upcoming clinical trials testing new therapies in FSHD.

Objective

This study aimed to explore the disease burden and patient preferences of people with FSHD to ensure that clinical trials can be designed to include outcome measures that are relevant and important to patients.

Methods

A survey was developed with a steering committee clinicians and physiotherapists with relevant experience in the disease, patient representatives, a registry expert and industry consultants. Themes of the survey included; participant demographics, disease progression and impact on function, factors encouraging or discouraging clinical trial participation, and positive outcomes of a clinical trial.

Results

1147 participants responded to the online survey, representing 26 countries across Europe and a range of disease severities. The study highlighted the key symptoms causing concern for FSHD patients - muscle weakness and mobility issues - reflecting what participants want targeted for future therapies. The need for clear information and communication throughout clinical trials was emphasised. Factors most encouraging trial participation included access to new investigational therapies, access to trial results and benefits for the FSHD community. Factors most discouraging trial participation included travel related issues and fear of side effects.

Conclusions

The results from this study identify the patient reported burden of FSHD and should provide researchers and industry with areas of therapeutic research that would be meaningful to patients, as well as supporting the development of patient centric outcome measures in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralHumansTravelTravel-Related IllnessCost of IllnessMuscle WeaknessPatient Reported Outcome Measures

Stichwörter der Autor:innen

Facioscapulohumeral muscular dystrophy (FSHD)clinical trialsdecision-makingpatient preferencespatient reported outcomestherapies

Autor:innen und Institutionen

  • John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK.
  • FSHD Europe, Radboud University Medical Centre, Department of Neurology, HB Nijmegen, TheNetherlands.
  • F. Hoffmann-La Roche Ltd, PD Data Sciences, Welwyn Garden City, UK.
  • Fulcrum Therapeutics, Inc., Cambridge, UK.
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK.
  • Unità Operativa Complessa di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Zitieren

APA

McNiff, M. M., Hawkins, S., Haase, B., Bullivant, J., McIver, T., Mitelman, O., Emery, N., Tasca, G., Voermans, N., & Diaz-Manera, J. (2024). Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation. Journal of Neuromuscular Diseases, 11(2), 459-472. https://doi.org/10.3233/jnd-230171

Vancouver

McNiff MM, Hawkins S, Haase B, Bullivant J, McIver T, Mitelman O, et al. Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation. Journal of Neuromuscular Diseases. 2024;11(2):459-472. doi:10.3233/jnd-230171

BibTeX
@article{McNiff2024,
  author = {McNiff, Megan M and Hawkins, Sheila and Haase, Bine and Bullivant, Joanne and McIver, Tammy and Mitelman, Olga and Emery, Nicholas and Tasca, Giorgio and Voermans, Nicol and Diaz-Manera, Jordi},
  title = {Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation},
  journal = {Journal of Neuromuscular Diseases},
  year = {2024},
  volume = {11},
  number = {2},
  pages = {459--472},
  doi = {10.3233/jnd-230171}
}
Kostenlos starten →